Providing adjuvant nivolumab (Opdivo, Bristol Myers Squibb) after radical resection continues to yield clinically meaningful disease-free survival (DFS) for people with muscle-invasive bladder cancer (MIBC), according to three-year median follow-up results of the phase 3 CheckMate 274 trial.
In a separate trial (CheckMate 9ER), final follow-up results confirmed that nivolumab plus cabozantinib is the standard of care for previously untreated advanced renal cell carcinoma (RCC).
Both studies were